IPR: Patents, Copyright & Trade Compliance

1. WHY IPR MATTERS: RATIONALE & PATENT SAFEGUARDS

Cue Words	Notes
Core Rationale for IP Protection	IPR grants creators **legal, time-bound ownership** over inventions, works, and marks — incentivising R&D and creative investment by allowing exclusive commercial exploitation for a defined period. **Patent term**: 20 years from filing under the TRIPS-aligned Patents Act, after which the invention enters the public domain (generic manufacturing becomes legal). **Utility Model** ("petty patent"): A lower-bar IP route — no inventive-step test, only novelty and industrial applicability required — with a shorter protection term of 6-15 years; often proposed as a low-cost option for India's MSME/grassroots innovators who cannot meet full patent standards. **Other IP terms**: Trademarks — 10 years, renewable indefinitely. Industrial designs (Designs Act, 2000) — maximum validity 15 years. GIs — 10 years, renewable in further 10-year blocks. Trade secrets — protected only as long as not independently discovered or disclosed (no fixed term; governed by Section 27 of the Contract Act, 1872, with no dedicated statutory codification).
Anti-Evergreening: Section 3(d)	**Section 3(d)** bars patents on new forms of known substances unless they show significantly enhanced therapeutic efficacy — blocking pharma companies from "evergreening" patents through trivial reformulation. The Novartis Gleevec ruling (Supreme Court, 2013) is the defining precedent. **Price impact**: Patented cancer drug Glivec costs ~₹1.2 Lakh/month; the Section 3(d)-enabled domestic generic equivalent costs **₹8,000-10,000/month**. **Patentability exclusions**: India's Patents Act, 1970 also excludes mere scientific discoveries/abstract theories, plant/animal varieties and their biological breeding processes, methods of medical treatment, traditional knowledge (e.g., Ayurvedic formulations), mathematical formulas, business methods, game-playing methods, and computer programs *per se* — a policy balance against overly broad IP claims over publicly shared knowledge and essential-service methods.
Compulsory Licensing & Farmer Seed Rights	**Compulsory Licensing** (Section 84): Lets government authorise generic production of a patented drug during a public-health emergency without the patent holder's consent (India's only invocation to date: Bayer's Nexavar, 2012). **Section 92** additionally empowers government to license a patented invention without consent during a national emergency, extreme urgency, or for public non-commercial use — both are TRIPS-permitted flexibilities balancing patent-holder rights against public-health/access imperatives. **Parallel importation** — importing a patented product without the patent-holder's consent for that market, even though legitimately marketed abroad by/with the patent-holder's consent — is illustrated by Pfizer selling Lipitor for $1/pill in Congo, far below wealthier-market prices, highlighting the tension between differential pricing and IP enforcement across jurisdictions. **PPV&FR Act**: Protects new plant varieties while carving out farmers' right to save, use, and re-sow harvested seed — India's distinctive *sui generis* approach, distinct from UPOV-style regimes. **Generic drugs**: equivalent in dosage, safety, strength and quality to the original, legally marketable once a drug's 20-year patent expires, or earlier via compulsory licensing — a key IPR-pharma policy tool for affordable-medicine access.

> **Summary**: India's patent regime is deliberately calibrated for access — Section 3(d), compulsory licensing (Sections 84 & 92), and farmer seed-saving rights each subordinate pure monopoly protection to public-health and food-security imperatives.

2. TRIPS COMPLIANCE & INTERNATIONAL FRICTION

Cue Words	Notes
TRIPS and WTO Obligations	**TRIPS Agreement** requires WTO members to standardise minimum IP protection — India complied by introducing product patents for pharmaceuticals and agrochemicals in 2005, ending the earlier process-patent-only regime that had enabled its generics industry to flourish. **Berne Convention** coordination extends copyright protection across borders, covering software source code — critical for India's IT services export credibility.
USTR Special 301 Pressure	India persists on the USTR's Special 301 Priority Watch List, reflecting sustained US industry pressure for tighter pharma-patent enforcement and curbs on compulsory licensing — a recurring bilateral trade irritant that surfaces in every USTR annual review.

> **Summary**: TRIPS accession reshaped India's patent law fundamentally in 2005, but the resulting system still draws sustained trade pressure (Special 301) because India continues to prioritise generic-drug access over the stronger enforcement Western pharma lobbies seek.

3. FILING MOMENTUM, PROCEDURAL & ENFORCEMENT REFORMS (2025-26)

Cue Words	Notes
Institutional Architecture & Filing Surge	**National IPR Policy** ("Creative India; Innovative India"): brings all IP administration — Patents, Designs, Trademarks, GI, Copyrights — under the **DPIIT** (Ministry of Commerce) via the CGPDTM, with **CIPAM** as the nodal agency driving IPR awareness. **Expedited Examination** fast-tracks patent grants for startups, MSMEs, and female applicants. **Filing Surge**: Patent applications rose to **1,43,729 in FY 2025-26**, a 30.2% jump over the prior year and India's highest-ever annual filing count — making India the 6th largest patent filer globally. Domestic (resident) filings now form **~69%** of the total (up from 61.8%), confirming a sustained shift from foreign-dominated to indigenous filing. **Longer-run trajectory**: Filings had already hit a record 90,300 in FY24 (~24% YoY growth, domestic applicants first outnumbering foreign filers at 52.2%), with annual grants rising to ~1,01,000 (from just 6,000 in 2014) as examination time fell from 72 months (2016) to 12-18 months — though still under 5-7% of granted patents get commercialised. Over 95% of patent/trademark applications are now filed online, with real-time tracking and video-conferenced hearings.
Patents (Amendment) Rules, 2025	Notified 25 November 2025, operational from January 2026: introduces administrative adjudication powers for designated Patent Office officers (an alternative to court litigation), revised penalty structures for procedural lapses, and updated CRI examination guidelines covering AI, Machine Learning, Blockchain, and Quantum Computing inventions. A parallel B1 Patent Specification publication-format change (effective 26 January 2026) improves the structural quality and searchability of granted-patent data in the IP India database.
EU-India FTA IP Chapter	The EU-India FTA, concluded 27 January 2026, includes an IP chapter industry observers expect will tighten remedies and border-enforcement measures once ratified — a new layer of obligation beyond baseline TRIPS commitments, relevant to India's balancing act between access and enforcement.

> **Summary**: The FY2025-26 filing surge to 1.43 Lakh applications, with resident filers near 70% of the total, shows the National IPR Policy's institutional consolidation (DPIIT/CIPAM) translating into measurable indigenous innovation. The 2025-26 reform cycle (Patent Rules amendment, B1 format, EU-India FTA) is procedural and enforcement-focused rather than substantive — it speeds up and digitises the system without touching the access-oriented safeguards (3(d), compulsory licensing) that remain India's defining IP posture.

3A. DESIGNS ACT, 2000 — PROPOSED AMENDMENTS 2026

Cue Words	Notes
DPIIT Concept Note (29 Jan 2026)	DPIIT released a Concept Note proposing amendments to the Designs Act, 2000 to modernise India's design-protection framework, under the "Design in India, Design for the World" vision. Proposes India's accession to the Riyadh Design Law Treaty (DLT) and the Hague Agreement Concerning the International Registration of Industrial Designs.
Key Proposals	**Virtual designs**: extending design protection to virtual designs by amending the definitions of **'article'** and **'design'**. **Grace period**: a **full grace period of 12 months**. **Deferred publication**: an option to **defer publication of a design for up to 30 months**.

> **Summary**: The proposed Designs Act amendments pursue international harmonisation (Riyadh DLT, Hague Agreement) alongside substantive modernisation — virtual-design protection, a 12-month grace period, and 30-month deferred publication — extending India's IP-reform push beyond patents into industrial designs.

4. NEW FRONTIERS: AI TRAINING DATA, TKDL & GEOGRAPHICAL INDICATIONS

Cue Words	Notes
Copyright and AI: The Unsettled Question	India has no settled statutory position on whether training AI models on copyrighted text/images constitutes infringement or fair use — a gap increasingly urgent as the IndiaAI Mission scales domestic foundation-model development on large text corpora, unlike jurisdictions already litigating this (e.g., US cases against OpenAI, Meta). Proposals for a collective-licensing/royalty mechanism (e.g., a Copyright Royalties Collective for AI Training-style body) to compensate authors and publishers when their work trains commercial models remain at a discussion stage.
TKDL: Defensive Prior-Art Against Biopiracy	**Traditional Knowledge Digital Library (TKDL)**: digitises traditional medical knowledge (Ayurveda, Siddha, Unani, Yoga) — used by over 70% of India's population — in 5 international languages, giving patent examiners worldwide prior-art evidence to block biopiracy claims. Covers **4.5 Lakh traditional formulations**, having blocked **250+ biopiracy patent attempts** internationally. **Origin**: traces to India's successful fight to revoke a USPTO patent on turmeric's wound-healing properties; a 2005 TKDL expert-group study estimated roughly 2,000 wrongful patents on Indian systems of medicine were being granted internationally each year, largely because this knowledge exists in local languages (Sanskrit, Hindi, Arabic, Urdu, Tamil, etc.) inaccessible to foreign patent examiners. **Trade-offs**: TKDL aids informed decision-making, public accessibility, and indigenous-research benefits, but critics flag risks of data theft, discouraged investment, and inadequate benefit-sharing with indigenous knowledge-holders.
Geographical Indications as Export & Livelihood Tool	India has registered over 643 GIs, protecting an estimated 11 Million rural artisans and growers (e.g., Darjeeling Tea, Basmati Rice, Kandhamal Haldi, Banarasi Sarees, Kanchipuram Silk) from commercial naming fraud/unauthorised imitation, sustaining export premiums and rural livelihoods — led by Uttar Pradesh (69 GIs) and Tamil Nadu (58).
Institutional & Enforcement Backbone	India ranks 2nd globally in trademark filings (4.5 Lakh+/year) and 39th on the WIPO Global Innovation Index (up from 81st in 2015); dedicated IP divisions were set up in the Delhi and Madras High Courts after the IPAB's 2021 dissolution. The SIPP scheme gives startups an 80% patent-fee rebate.

> **Summary**: The unresolved AI-copyright question, TKDL's biopiracy-defence role, and the expanding commercial use of GI tags mark where Indian IP policy is actively being stretched by new economic and technological demands — reinforced by a strengthening institutional backbone (specialised IP courts, rising WIPO ranking, startup fee rebates).

5. TKDL: INDIA-BRAZIL ACCESS AGREEMENT 2026

Cue Words

Notes

India-Brazil TKDL Access Agreement (21 Feb 2026)

India and Brazil signed a **TKDL (Traditional Knowledge Digital Library) Access Agreement** on 21 Feb 2026, during Brazilian President Lula's state visit to India (18-22 Feb 2026, for the AI Impact Summit) — signed between **CSIR (India)** and **INPI** (Brazil's patent office). With Brazil's inclusion, **18 patent offices worldwide** now have TKDL access. TKDL was established in **2001** by CSIR + Ministry of AYUSH to prevent erroneous patenting/biopiracy of Indian traditional knowledge (Ayurveda, Unani, Siddha, Sowa Rigpa, Yoga) — it now contains **over 5.2 lakh formulations**, available in **5 international languages**. **Over 375 patent applications** worldwide have been revoked/rejected/amended/withdrawn using TKDL prior-art evidence.

> **Summary**: The Brazil agreement extends TKDL's defensive-prior-art network to 18 patent offices, reinforcing its role as India's principal tool against biopiracy of traditional-knowledge systems.

UPSC Mains PYQs

• IPR & Evergreening: In the context of the Intellectual Property Rights (IPR) regime, discuss the significance of Section 3(d) of the Indian Patents Act, 1970. Analyse the debate between multinational pharmaceutical companies and domestic generic manufacturers regarding evergreening of patents. (15 Marks, 250 Words)
• Patent Filing Trends: Account for the record surge in India's patent filings in recent years, with particular reference to the rising share of resident applicants and the Patents (Amendment) Rules, 2025. (10 Marks, 150 Words)
• Compulsory Licensing: Discuss the scope and limitations of compulsory licensing as a public-health tool under Indian patent law, citing relevant case law. (15 Marks, 250 Words)
• TRIPS and Generic Drug Industry: Assess the impact of TRIPS compliance on India's generic pharmaceutical industry since 2005. (15 Marks, 250 Words)
• Farmers' Seed Rights: Explain how the PPV&FR Act balances plant breeders' IP rights with farmers' traditional seed-saving practices. (10 Marks, 150 Words)
• AI and Copyright Law: What challenges does generative AI training pose for India's copyright regime, and how might they be addressed? (10 Marks, 150 Words)
• Geographical Indications: Discuss the role of Geographical Indication registration in protecting India's traditional products and boosting rural livelihoods. (10 Marks, 150 Words)
• Recent IP Reforms: Evaluate the significance of the 2025-26 patent procedural reforms and the EU-India FTA's IP chapter for India's enforcement landscape. (15 Marks, 250 Words)